Systolic hypertension in older persons.
In summary, elevated levels of SBP are the single greatest cardiovascular risk factor in patients over 65 years of age. Adequate clinical data exist to indicate that ISH can be treated effectively with a minimum amount of side effects in most elderly patients. The SHEP main trial has now definitely proved that treating ISH lowers cerebrovascular coronary heart disease, and total cardiovascular morbidity and mortality. See Table 3 for antihypertensive treatment recommendations in elderly patients.